Akari Therapeutics (AKTX) Long-Term Debt Issuances (2014 - 2015)
Akari Therapeutics (AKTX) reported Long-Term Debt Issuances of $529935.0 for Q4 2015, up 22.57% on a YoY basis from $432353.0 in Q4 2014, and up 22.57% sequentially from $432353.0 in Q4 2014.
Akari Therapeutics (AKTX) Long-Term Debt Issuances (2014 - 2015) Analysis & Trends
Akari Therapeutics (AKTX) has 2 years of Long-Term Debt Issuances data on file, last reported at $529935.0 in Q4 2015.
- For the quarter ending Q4 2015, Long-Term Debt Issuances rose 22.57% year-over-year to $529935.0; the trailing twelve-month figure through Dec 2025 stood at $529935.0 (down 44.93% YoY), and the FY2025 full-year result was $2.1 million, up 109.9% from the prior year.
- Long-Term Debt Issuances improved to $529935.0 in Q4 2015, from $432353.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $529935.0 in Q4 2015 to a low of $432353.0 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 529,935.00 |
| Dec 31, 2015 | 529,935.00 |
| Dec 31, 2014 | 432,353.00 |
| Dec 31, 2014 | 432,353.00 |